Ocular Therapeutix is a Bedford, MA biopharma advancing AXPAXLI, an axitinib hydrogel for wet AMD in Phase 3. Its stack pairs SAP S/4HANA, SAP Master Data Governance and Informatica with LabWare LIMS and Veeva Vault, and job posts cite an ERP upgrade data migration plus new QC software. Accelerating, sales-led, director-heavy hiring alongside reimbursement and payer pull-through work points to commercial-launch preparation.
Notable leadership hires: Account Director, Facilities Director
Ocular Therapeutix, founded in 2006 and headquartered in Bedford, Massachusetts, is a public biopharmaceutical company focused on retinal disease. Its lead investigational candidate, AXPAXLI (OTX-TKI), is an axitinib hydrogel given by intravitreal injection and built on the company's ELUTYX sustained-delivery technology. The candidate is in Phase 3 trials for wet AMD, with potential use in NPDR and DME. The company employs 51–200 people and hires in the United States across sales, manufacturing, engineering, operations and finance.
Ocular Therapeutix uses SAP S/4HANA, SAP Master Data Governance, Informatica, LabWare LIMS, Veeva Vault, Veeva CRM, Salesforce, QAD, Oracle, ADP Workforce Now, SolidWorks and Azure Portal.
Yes. Sales is the largest hiring area, with director-level roles such as Account Director, alongside manufacturing, engineering, operations and finance roles in the United States.
Job posts point to process performance qualification, technology transfer and validation, an ERP upgrade data migration, new QC software, and a government account strategy for AXPAXLI.
Other companies in the same industry, closest in size
Ocular Therapeutix, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.
